Inventor · disambiguated record
Alexander Muik
Also filed as: MUIK ALEXANDER
10 granted patents·28 pending applications·17 citations·filing 2019–2025
84Inventor score
Top patents by PatentIndex Score
38 records- 0194US11547673B1Coronavirus vaccineBioNTech SE·Filed 2021·Granted Jan 10, 2023·12 cites·45 claims
- 0292US11878055B1Coronavirus vaccineBioNTech SE·Filed 2023·Granted Jan 23, 2024·2 cites·30 claims
- 0389US11925694B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Mar 12, 2024·1 cites·36 claims
- 0486US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 0586US2025242059A1Coronavirus vaccineBioNTech SE·Filed 2024·Application pending·0 cites
- 0682US10968280B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2020·Granted Apr 6, 2021·1 cites·12 claims
- 0781US12133899B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Nov 5, 2024·0 cites·24 claims
- 0879US12208136B2Coronavirus vaccineBioNTech SE·Filed 2023·Granted Jan 28, 2025·0 cites·28 claims
- 0977US2023087745A1Binding agents binding to pd-l1 and cd137 and use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 1073US12186387B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Jan 7, 2025·0 cites·28 claims
- 1173US2023212301A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1273US2024366751A1Coronavirus vaccineBioNTech SE·Filed 2023·Application pending·0 cites
- 1372US2023109496A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1471US2025289900A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 1571US2025289899A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 1662US2024383947A1Virus vaccineBioNTech SE·Filed 2022·Application pending·0 cites
- 1760US2024355417A1Systems and methods for detection, monitoring, and interactive display of circulating infectious diseases and their characteristicsBioNTech SE·Filed 2024·Application pending·0 cites
- 1859US2025325643A1Binding agents capable of binding to cd27 in combination therapyGENMAB AS·Filed 2023·Application pending·0 cites
- 1958US12398214B2Binding agents binding to EpCAM and CD137GENMAB AS·Filed 2023·Granted Aug 26, 2025·0 cites·24 claims
- 2058US2024321387A1Immunogen selectionBioNTech SE·Filed 2022·Application pending·0 cites
- 2158US2024339174A1Technologies for early detection of variants of interestBioNTech SE·Filed 2022·Application pending·0 cites
- 2258US2024409653A1Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancersGENMAB AS·Filed 2022·Application pending·0 cites
- 2358US2024262924A1Combination dosage regime of cd137 and pd-l1 binding agentsGENMAB AS·Filed 2022·Application pending·0 cites
- 2457US11932693B2Monoclonal antibodies directed against programmed death-1 protein and their use in medicineBioNTech SE·Filed 2023·Granted Mar 19, 2024·0 cites·30 claims
- 2556US2024109972A1Antibody and taxane combination therapyGENMAB AS·Filed 2021·Application pending·0 cites
- 2655US2023201817A1Modular drug production systemBIONTECH DELIVERY TECH GMBH·Filed 2022·Application pending·0 cites
- 2755US2025002600A1Multispecific binding agents against pd-l1 and cd137 in combination therapyGENMAB AS·Filed 2022·Application pending·0 cites
- 2855US2025222096A1Coronavirus vaccineBioNTech SE·Filed 2021·Application pending·0 cites
- 2953US2024335511A1Therapeutic rna for treating cancerBioNTech SE·Filed 2021·Application pending·0 cites
- 3052US2024327544A1Multispecific binding agents against cd40 and cd137 in combination therapy for cancerBioNTech SE·Filed 2022·Application pending·0 cites
- 3151US2023087164A1Antibodies for use in therapyGENMAB AS·Filed 2021·Application pending·0 cites
- 3250US2021369842A1Antibody formulationGENMAB AS·Filed 2019·Application pending·0 cites
- 3349US2023117803A1Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137BioNTech SE·Filed 2021·Application pending·0 cites
- 3448US2023287088A1Binding agents for coronavirus s proteinBioNTech SE·Filed 2021·Application pending·0 cites
- 3548US2023399403A1Monoclonal antibodies directed against programmed death-1 protein and their use in medicineBioNTech SE·Filed 2021·Application pending·0 cites
- 3647US2022143144A1Treatment involving interleukin-2 (il2) and interferon (ifn)BioNTech SE·Filed 2020·Application pending·0 cites
- 3746US2024002127A1Coronavirus vaccinePFIZER·Filed 2021·Application pending·0 cites
- 3844US2022356223A1IL2 AgonistsBioNTech SE·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexander Muik files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →